Kimme Hyrich

Jul 8, 2024 | acrjournals.onlinelibrary.wiley.com | Sizheng Zhao |Kimme Hyrich |Zenas Yiu |Anne Barton

INTRODUCTION Inhibitors of the interleukin 13 (IL-13) pathway, such as dupilumab (dual interleukin 4 [IL-4]/IL-13 inhibitor), tralokinumab, and lebrikizumab (pure IL-13 inhibitors), were developed to treat atopic diseases including atopic dermatitis, chronic rhinosinusitis, and asthma.1-4 Musculoskeletal adverse events resembling seronegative spondyloarthritis have been reported after dupilumab initiation, but evidence is limited to case series and spontaneous pharmacovigilance with uncertain...

Feb 8, 2024 | ard.bmj.com | Kate E Duhig |Kimme Hyrich

Annals of the Rheumatic Diseases collection on pregnancy 2018–2023: observational data-driven knowledge Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Sep 27, 2023 | academic.oup.com | Kimme Hyrich

This study aimed to evaluate if and how the incidence of serious infection (SI) and active tuberculosis (TB) differ among seven biological disease-modifying antirheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA) considering the line of therapy.